Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972109 · ClinicalTrials.gov registry record · NA
Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling
A NA study of Insulin Sensitivity and Obesity, Abdominal, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 604
- Enrollment target
- 1
- Study location
NCT05972109: Completed NA study of Insulin Sensitivity and Obesity, Abdominal, sponsored by University of California, San Francisco.
NCT05972109 is a NA study of Insulin Sensitivity and Obesity, Abdominal that has completed, run by University of California, San Francisco. The registered enrollment target is 604 participants, above the 52-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (1062% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05972109, a NA study of Insulin Sensitivity and Obesity, Abdominal, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 604 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to test the impact of a multilevel workplace intervention (hospital-wide sales ban on sugar-sweetened beverages (SSBs) and individual-level brief counseling) on employee health.
Primary Outcome
Waist circumference in centimeters (using method from Multi-Ethnic Study of Atherosclerosis). The study will measure the change between baseline and 12 month Abdominal Adiposity measurements.
Conditions Studied
Interventions
- BEHAVIORAL Brief Intervention
- OTHER Workplace SSB sales ban
Study Locations (1)
California
- Sutter Health/California Pacific Medical Center Research Institute - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 604 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2026-02-01 |
| Phase | NA |
What the finished NCT05972109 record still lists
NCT05972109 is an interventional study that assigns participants to a tested intervention. The registered 604 participants enrollment target is mid-sized for trials with a published cap, above the 52-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (1062% higher).
The record links to 2 conditions, with Insulin Sensitivity appearing as the primary indexed condition, and to 2 interventions - of which Brief Intervention is the first listed.
NCT05972109 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05972109 about?
NCT05972109 is a clinical study titled "Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling". The purpose of the study is to test the impact of a multilevel workplace intervention (hospital-wide sales ban on sugar-sweetened beverages (SSBs) and individual-level brief counseling) on employee health.
What is the current status of trial NCT05972109?
This trial is currently completed. It is a NA study. The enrollment target is 604 participants. The study started on 2023-08-01. Estimated completion is 2026-02-01.
What conditions does trial NCT05972109 study?
This clinical trial studies the following conditions: Insulin Sensitivity, Obesity, Abdominal.
What interventions are being tested in trial NCT05972109?
The interventions under investigation include: Brief Intervention (BEHAVIORAL), Workplace SSB sales ban (OTHER).
Who is sponsoring clinical trial NCT05972109?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972109 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Sensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05972109's enrollment target sits among peer trials
604 1st of 29 higher than 29 of 29 other Insulin Sensitivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Sensitivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Countermeasures to Circadian Misalignment
RECRUITING · NA
-
Effect of Pulsatile Hormone Administration on Insulin Action
RECRUITING · NA
-
Mechanisms of Ultrasound Neuromodulation Effects in Diabetes
RECRUITING · NA
-
Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI